Market research
PYC.LSE Physiomics Plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- Not available
- Beta
- 1.04
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BDR6W943
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- Not available
- Beta
- 1.04
About
About Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PYC.LSE discussion.
5 years, 5 months ago
Physiomics Plc is currently in a long term downtrend where the price is trading 8.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.1.
Physiomics Plc's total revenue sank by 0.0% to $172K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-41K since the same quarter in the previous year.
Finally, its free cash flow grew by 96.6% to $28K since the same quarter in the previous year.
Based on the above factors, Physiomics Plc gets an overall score of 2/5.